Pfizer Inc. (PFE)
Pfizer could move outside manufacturing to the US, says CEO
Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to the U.S., if required, as President Donald Trump's administration threatens numerous tariffs on imported goods.
2 Top Stocks Beaten Down Near 52-Week Lows That Look Like Bargains Now
Buying low to sell later when the stock's price is high is a time-honored investing strategy. With the benchmark S&P 500 index near its all-time high, though, now might seem like the wrong time to go looking for stocks that trade at bargain prices.
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer
SMMT's Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab's development beyond the NSCLC indication.
Pfizer names former FDA director Patrizia Cavazzoni as chief medical officer
Pfizer said on Monday former head of FDA's drug center, Patrizia Cavazzoni, will join the drugmaker as chief medical officer.
Pfizer: What The Summit Therapeutics Deal Brings
Pfizer: What The Summit Therapeutics Deal Brings
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer: No More Growth - Still A Worthy Dividend Buy
PFE's sell-off triggers a rich dividend yield of 6.73% and double digits capital appreciation prospects, thanks to management's focus to "enhancing long-term shareholder value." Despite the patent cliff headwinds and IRA Medicare Part D redesign impacts, its core portfolios and strategic acquisitions demonstrate robust growth profile, particularly in oncology. These developments underscore why the management's focus on intensified business developments and R&D efforts has been well justified.
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Looking for a good area in which to invest? Consider the healthcare sector.
Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports
Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.
Why Pfizer's Stock Price Isn't Reflecting Its True Value
Pfizer's EPS and revenue beat my expectations, mainly due to strong sales of its anti-cancer medications. So, Xtandi sales amounted to $565 million in the fourth quarter of 2024, an increase of 79.9% year-on-year. A key contributor to its strong performance was its Vyndaqel family, whose sales grew more than 60% year over year.
Pfizer CEO Albert Bourla: Focusing on opportunities outside of vaccines with RFK Jr.
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.
